Brief: Grifols Says Positive Fibrinogen Phase 3 Trial Results Published

Grifols SA

19/06/2025 13:10

June 19 (Reuters) - Grifols SA GRLS.MC:

POSITIVE FIBRINOGEN PHASE 3 TRIAL RESULTS PUBLISHED IN THE LANCET'S ECLINICALMEDICINE

PHASE 3 ADFIRST STUDY MET PRIMARY ENDPOINT

FIBRINOGEN CONCENTRATE BT524 WAS NON-INFERIOR TO STANDARD CARE FOR TREATMENT OF BLEEDING IN ACQUIRED FIBRINOGEN DEFICIENCY (AFD)

FIBRINOGEN BT524 ON TRACK TO LAUNCH IN EUROPE LATER THIS YEAR AND, PENDING FDA APPROVAL, IN THE U.S. IN EARLY 2026

Source text: https://tinyurl.com/2e39k2ax

Further company coverage: GRLS.MC

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com;))